In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Standard BioTools Inc’s stock clocked out at $1.2, up 0.84% from its previous closing price of $1.19. In other words, the price has increased by $0.84 from its previous closing price. On the day, 1.85 million shares were traded. LAB stock price reached its highest trading level at $1.24 during the session, while it also had its lowest trading level at $1.16.
Ratios:
To gain a deeper understanding of LAB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.37 and its Current Ratio is at 6.12. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 16, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $3.50.
On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.Jefferies initiated its Buy rating on April 04, 2024, with a $3.25 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 23 ’25 when Kim Hanjoon Alex sold 1,428 shares for $0.94 per share. The transaction valued at 1,344 led to the insider holds 930,286 shares of the business.
Mackay Sean sold 13,217 shares of LAB for $12,437 on May 23 ’25. The SVP & Chief Business Officer now owns 843,076 shares after completing the transaction at $0.94 per share. On May 23 ’25, another insider, Egholm Michael, who serves as the President & CEO of the company, sold 5,473 shares for $0.94 each. As a result, the insider received 5,150 and left with 2,741,191 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 433490400 and an Enterprise Value of 175179392. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.69 while its Price-to-Book (P/B) ratio in mrq is 1.00. Its current Enterprise Value per Revenue stands at 1.032 whereas that against EBITDA is -1.586.
Stock Price History:
The Beta on a monthly basis for LAB is 1.54, which has changed by -0.32203388 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, LAB has reached a high of $2.41, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is 8.41%, while the 200-Day Moving Average is calculated to be -19.97%.
Shares Statistics:
It appears that LAB traded 1.72M shares on average per day over the past three months and 4111240 shares per day over the past ten days. A total of 379.09M shares are outstanding, with a floating share count of 367.76M. Insiders hold about 3.18% of the company’s shares, while institutions hold 72.28% stake in the company. Shares short for LAB as of 1749772800 were 16159588 with a Short Ratio of 9.38, compared to 1747267200 on 17493417. Therefore, it implies a Short% of Shares Outstanding of 16159588 and a Short% of Float of 7.249999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
